CN101152186A - 黄体酮注射液及其制备方法 - Google Patents
黄体酮注射液及其制备方法 Download PDFInfo
- Publication number
- CN101152186A CN101152186A CNA200710049940XA CN200710049940A CN101152186A CN 101152186 A CN101152186 A CN 101152186A CN A200710049940X A CNA200710049940X A CN A200710049940XA CN 200710049940 A CN200710049940 A CN 200710049940A CN 101152186 A CN101152186 A CN 101152186A
- Authority
- CN
- China
- Prior art keywords
- progesterone
- oil
- injection
- preparation
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 218
- 239000000186 progesterone Substances 0.000 title claims abstract description 109
- 229960003387 progesterone Drugs 0.000 title claims abstract description 109
- 238000002347 injection Methods 0.000 title claims abstract description 84
- 239000007924 injection Substances 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 17
- 239000003381 stabilizer Substances 0.000 claims abstract description 10
- 239000000839 emulsion Substances 0.000 claims description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- -1 15-hydroxy stearic acid ester Chemical class 0.000 claims description 32
- 239000003921 oil Substances 0.000 claims description 30
- 235000019198 oils Nutrition 0.000 claims description 30
- 239000002202 Polyethylene glycol Substances 0.000 claims description 27
- 229920001223 polyethylene glycol Polymers 0.000 claims description 27
- 239000003549 soybean oil Substances 0.000 claims description 19
- 235000012424 soybean oil Nutrition 0.000 claims description 19
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 17
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 17
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 17
- 239000000467 phytic acid Substances 0.000 claims description 17
- 229940068041 phytic acid Drugs 0.000 claims description 17
- 235000002949 phytic acid Nutrition 0.000 claims description 17
- 229910052708 sodium Inorganic materials 0.000 claims description 17
- 239000011734 sodium Substances 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 17
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 16
- 239000008347 soybean phospholipid Substances 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 210000003022 colostrum Anatomy 0.000 claims description 14
- 235000021277 colostrum Nutrition 0.000 claims description 14
- 238000012856 packing Methods 0.000 claims description 13
- 239000008215 water for injection Substances 0.000 claims description 13
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 12
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 239000005642 Oleic acid Substances 0.000 claims description 12
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 12
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 12
- 239000004006 olive oil Substances 0.000 claims description 11
- 235000008390 olive oil Nutrition 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 9
- 239000012982 microporous membrane Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 8
- 239000007957 coemulsifier Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 238000005352 clarification Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 238000007689 inspection Methods 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 238000011045 prefiltration Methods 0.000 claims 1
- 238000004500 asepsis Methods 0.000 abstract 1
- 235000019633 pungent taste Nutrition 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 18
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 11
- 229920001304 Solutol HS 15 Polymers 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 230000008859 change Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005286 illumination Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 101100489867 Mus musculus Got2 gene Proteins 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
产品 | 血压下降(mmHg) | 组胺释放(ng/ml) | 组胺释放发生率(>10ng/ml) |
吐温 | 115 | 400 | 8/8 |
HS-15 | 60 | 0 | 8/0 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710049940XA CN101152186B (zh) | 2007-09-05 | 2007-09-05 | 黄体酮注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710049940XA CN101152186B (zh) | 2007-09-05 | 2007-09-05 | 黄体酮注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101152186A true CN101152186A (zh) | 2008-04-02 |
CN101152186B CN101152186B (zh) | 2011-07-06 |
Family
ID=39254206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710049940XA Expired - Fee Related CN101152186B (zh) | 2007-09-05 | 2007-09-05 | 黄体酮注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101152186B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101947202A (zh) * | 2010-09-25 | 2011-01-19 | 洛阳惠中兽药有限公司 | 兽用微乳剂及其制备方法 |
WO2011134944A2 (en) | 2010-04-26 | 2011-11-03 | Besins Healthcare Luxembourg Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
CN102920657A (zh) * | 2012-11-30 | 2013-02-13 | 沈阳药科大学 | 16-妊娠双烯醇酮亚微乳注射剂及其制备方法 |
WO2013127727A1 (en) | 2012-02-29 | 2013-09-06 | B. Braun Melsungen Ag | Hormone containing emulsion comprising krill phospholipids |
CN103830177A (zh) * | 2014-03-05 | 2014-06-04 | 王栾秋 | 盐酸吉西他滨注射液及其制备方法 |
CN105497870A (zh) * | 2016-02-03 | 2016-04-20 | 许筱妹 | 一种治疗功能性子宫出血的复方片剂及其制备方法 |
CN105769765A (zh) * | 2016-03-22 | 2016-07-20 | 辅必成(上海)医药科技有限公司 | 己酸羟孕酮脂肪乳注射液 |
CN107441039A (zh) * | 2017-08-25 | 2017-12-08 | 南京斯泰尔医药科技有限公司 | 一种黄体酮混悬注射液及其制备方法 |
CN111346054A (zh) * | 2020-03-10 | 2020-06-30 | 上海图珐医药科技有限公司 | 一种黄体酮乳剂型注射剂及其制备方法 |
US10898432B2 (en) | 2015-12-18 | 2021-01-26 | Proinvet Innovations S.A. | Formulations and methods for controlling the reproductive cycle and ovulation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
CN1282459C (zh) * | 2002-12-24 | 2006-11-01 | 上海医药工业研究院 | 黄体酮胶丸及制备方法 |
CN1517091A (zh) * | 2003-01-16 | 2004-08-04 | 董英杰 | 黄体酮制剂及制备方法 |
-
2007
- 2007-09-05 CN CN200710049940XA patent/CN101152186B/zh not_active Expired - Fee Related
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2857042A1 (en) | 2010-04-26 | 2015-04-08 | Besins Healthcare Luxembourg | Low-oil pharmaceutical emulsion compositions comprising progestogen |
EP2801353A1 (en) | 2010-04-26 | 2014-11-12 | Besins Healthcare Luxembourg | Pharmaceutical Emulsion Compositions Comprising Progestogen |
WO2011134937A2 (en) | 2010-04-26 | 2011-11-03 | Besins Healthcare Luxembourg Sarl | Pharmaceutical emulsion compositions comprising progestogen |
WO2011134937A3 (en) * | 2010-04-26 | 2012-02-02 | Besins Healthcare Luxembourg Sarl | Pharmaceutical emulsion compositions comprising progestogen |
AU2011246527B2 (en) * | 2010-04-26 | 2016-09-15 | Besins Healthcare Luxembourg Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
EA022460B1 (ru) * | 2010-04-26 | 2016-01-29 | Безен Хелткэа Люксембург Сарл | Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген |
WO2011134944A2 (en) | 2010-04-26 | 2011-11-03 | Besins Healthcare Luxembourg Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
CN102946865A (zh) * | 2010-04-26 | 2013-02-27 | 博赏医药卢森堡责任有限公司 | 包含孕激素的低油的药物乳液组合物 |
WO2011134944A3 (en) * | 2010-04-26 | 2012-02-09 | Besins Healthcare Luxembourg Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
CN102946865B (zh) * | 2010-04-26 | 2016-06-22 | 博赏医药卢森堡责任有限公司 | 包含孕激素的低油的药物乳液组合物 |
CN102946864A (zh) * | 2010-04-26 | 2013-02-27 | 博赏医药卢森堡责任有限公司 | 包含孕激素的药物乳液组合物 |
CN101947202A (zh) * | 2010-09-25 | 2011-01-19 | 洛阳惠中兽药有限公司 | 兽用微乳剂及其制备方法 |
WO2013127728A1 (en) | 2012-02-29 | 2013-09-06 | B. Braun Melsungen Ag | Hormone containing emulsion |
WO2013127727A1 (en) | 2012-02-29 | 2013-09-06 | B. Braun Melsungen Ag | Hormone containing emulsion comprising krill phospholipids |
CN102920657B (zh) * | 2012-11-30 | 2015-06-10 | 沈阳药科大学 | 16-妊娠双烯醇酮亚微乳注射剂及其制备方法 |
CN102920657A (zh) * | 2012-11-30 | 2013-02-13 | 沈阳药科大学 | 16-妊娠双烯醇酮亚微乳注射剂及其制备方法 |
CN103830177A (zh) * | 2014-03-05 | 2014-06-04 | 王栾秋 | 盐酸吉西他滨注射液及其制备方法 |
US10898432B2 (en) | 2015-12-18 | 2021-01-26 | Proinvet Innovations S.A. | Formulations and methods for controlling the reproductive cycle and ovulation |
CN105497870A (zh) * | 2016-02-03 | 2016-04-20 | 许筱妹 | 一种治疗功能性子宫出血的复方片剂及其制备方法 |
CN105769765A (zh) * | 2016-03-22 | 2016-07-20 | 辅必成(上海)医药科技有限公司 | 己酸羟孕酮脂肪乳注射液 |
CN107441039A (zh) * | 2017-08-25 | 2017-12-08 | 南京斯泰尔医药科技有限公司 | 一种黄体酮混悬注射液及其制备方法 |
CN111346054A (zh) * | 2020-03-10 | 2020-06-30 | 上海图珐医药科技有限公司 | 一种黄体酮乳剂型注射剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101152186B (zh) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101152186B (zh) | 黄体酮注射液及其制备方法 | |
JP5887368B2 (ja) | 共溶媒処方物 | |
CN101708314B (zh) | 一种中药挥发油注射溶液及其注射剂和制备方法 | |
CN101224203B (zh) | 丹参酮ⅱa微乳制剂及制备方法 | |
CN101524330B (zh) | 一种微乳载药系统及制备方法 | |
WO2016177346A1 (zh) | 一种卡巴他赛脂肪乳注射剂及其制备方法和用途 | |
WO2010127541A1 (zh) | 长春花生物碱纳米乳剂注射液及其制备方法 | |
CN100375621C (zh) | 长春瑞滨脂质微球注射液及其制备方法 | |
CN114129574A (zh) | 一种甾体化合物的应用、含其的组合物及其制备方法 | |
CN101773470A (zh) | 注射用伊维菌素亚微乳液 | |
CN102048688A (zh) | 以胆固醇复合物为中间载体的紫杉醇亚微乳 | |
Deng et al. | Quality by design approach for the preparation of fat-soluble vitamins lipid injectable emulsion | |
CN102552137A (zh) | 雷公藤内酯醇脂肪乳注射剂及其制备方法 | |
CN100525753C (zh) | 辅酶q10亚微乳注射液及制备方法 | |
CN100386078C (zh) | 尼莫地平乳注射液及制备方法 | |
CN106109412A (zh) | 氟比洛芬酯脂微球注射液及其制备方法 | |
CN114028324B (zh) | 钩藤碱温敏凝胶鼻腔给药制剂及制备方法 | |
CN109758423A (zh) | 使用维生素k1脂肪乳注射液治疗凝血功能障碍的方法 | |
CN101485632B (zh) | 尼莫地平脂质微球注射液及其制备方法 | |
CN101249070B (zh) | 2-甲氧基雌二醇静脉纳米乳剂 | |
AU2020103417A4 (en) | Preparation of TN14003 Thermo-sensitive Gel for Treatment of Osteoarthritis by Intraarticular Injection | |
CN100502835C (zh) | 莪术油亚微乳剂及制备方法 | |
CN103747780A (zh) | 亲脂性物质的水溶液,特别是药物物质溶液 | |
CN105560216A (zh) | 一种恩替卡韦固体脂质纳米粒及其制备方法 | |
CN101422454B (zh) | ω-3多不饱和脂肪酸丹参酮ⅡA亚微乳及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HANGZHOU PINGHE ANKANG MEDICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: ZHANG WEIQUN Effective date: 20110419 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310008 15-1-302, HAIYUE GARDEN, FUXING ROAD, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 310018 ROOM 302, UNIT 1, BUILDING 15, HAIYUE GARDEN, FUXING ROAD, SHANGCHENG DISTRICT, HANGZHOU CITY, ZHEJIANG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110419 Address after: Hangzhou City, Zhejiang province 310018 Fuxing Road, Shangcheng district 15 Sea Garden Building 1 unit 302 room Applicant after: Hangzhou Pingheankang Pharmaceutical Technology Co., Ltd. Address before: 310008 Zhejiang province Hangzhou City Fuxing Road Garden on the sea 15-1-302 Applicant before: Zhang Weiqun |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: QUJING PINGHE ANKANG MEDICINE CO., LTD. Free format text: FORMER OWNER: HANGZHOU PINGHE ANKANG PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20140507 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310018 HANGZHOU, ZHEJIANG PROVINCE TO: 310008 HANGZHOU, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140507 Address after: Hangzhou City, Zhejiang province 310008 City Garden on the sea 15-1-302 Patentee after: Qu Jingping Ankang medical and health care Co., Ltd. Address before: Hangzhou City, Zhejiang province 310018 Fuxing Road, Shangcheng district 15 Sea Garden Building 1 unit 302 room Patentee before: Hangzhou Pingheankang Pharmaceutical Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110706 Termination date: 20160905 |